Introduction
Due to the negative stigma attached to being HIV-positive and consequent risks associated with serostatus disclosure, many HIV-positive people are selective about revealing their diagnosis, sometimes concealing it even from family and friends (Rao, Kekwaletswe, Hosek, Martinez, & Rodriguez, 2007) . Unlike disclosure decisions faced by people with behaviorally acquired HIV disease, disclosure by perinatally infected, HIV-positive children and adolescents (PIHCA) is uniquely embedded in a familial context. These PIHCA may face family pressure to maintain secrecy, given that diagnosis disclosure simultaneously exposes the serostatus of their biological mother and raises questions about other family members' serostatus if mode of infection is revealed or assumed (Vreeman et al., 2010) . Thus, PIHCA may lack full autonomy over the decision to share their diagnosis. Consequently, PIHCA may disclose to fewer friends than their behaviorally infected counterparts (Abramowitz et al., 2009) .
Maintenance of serostatus secrecy requires not only verbal self-restraint but also behavioral accom-modations, such as concealing medication and medication-taking activities. In a US sample of HIV-positive youth, Rao et al. (2007) found that many participants reported skipping doses and hiding their medication for fear friends or family might discover their serostatus. Such behavior has dangerous implications for disease management. Highly active antiretroviral therapy (HAART) necessitates strict adherence to slow disease progression (Kitahata et al., 2004) and involves not only medication dosage, but also dose timing. To the extent that patients' efforts to conceal their serostatus alter dose taking and timing, such behavior could be detrimental to their health. Thus, opting not to disclose to friends could indirectly compromise PIHCA's medical functioning.
To date, research examining peer disclosure among PIHCA relative to medical outcomes is limited and has yielded mixed results (e.g., Lam, Naar-King, & Wright, 2007; Sherman, Bonanno, Wiener, & Battles, 2000; Wiener & Battles, 2006) . The current study sought to examine medication hiding as a mediator of the relationship between *Corresponding author. Email: martins@mail.nih.gov Care Vol. 24, No. 9, September 2012 peer disclosure and multiple markers of medical functioning among PIHCA. We hypothesized that participants who had disclosed their serostatus to 1'friend(s) would report less medication hiding, which would relate to better medical functioning (see Figure 1) . A secondary objective, contingent on finding a significant indirect effect, was to explore the implications of number of friends disclosed to for medication hiding and medical functioning.
AIDS

Methods
Participants
The sample was comprised of 25 PIHCA from across the USA who were enrolled on a medical protocol at a government research institute via referral by their local medical providers. Patients were eligible for this substudy if they were aware of their serostatus and actively being prescribed HAART.
Measures
Diagnosis disclosure
Participants' disclosure of their serostatus to friends was assessed with one item: ''How many of your friends are aware of your HIV diagnosis?'' Response options were ''None,'' ''1Á3,'' ''4Á10,'' and ''11 or more.'' For the primary analyses with the full sample, the latter three options were combined to form an ''any disclosure'' subgroup that was compared to the ''no disclosure'' subgroup. Alternate category combinations were used to dichotomize the variable (1Á3 vs. 4'and 1Á10 vs. 11') in subsequent exploratory analyses.
Medication hiding
The extent to which participants concealed medication-taking from friends was assessed with one item: ''Do you hide the fact that you take medication from your friends?'' Response options ranged from ''Not at all'' (1) to ''Very much'' (4), with higher scores indicating greater hiding.
Medical functioning
Medical markers of HIV disease status included HIV1 RNA copies/ml (viral load), CD4'absolute cell counts, and CD4'percentages.
Background characteristics
Patients and caregivers completed a background form regarding sociodemographic and medical characteristics.
Procedure
Eligible patients and their caregivers were approached during outpatient clinic visits for their primary medical protocol and invited to participate in this substudy. Questionnaire and medical data were obtained during the same visit. All study procedures received IRB approval.
Analyses
Analyses were performed using SPSS (PASW 18.0.3). Pearson correlations were conducted to explore bivariate relationships between medication hiding and medical variables. Bootstrapping was used to Figure 1 . Hypothesized model of the indirect effects of diagnosis disclosure to friends on medical functioning via medication hiding. Medical functioning was operationalized in three different ways: (1) Viral load (HIV1 RNA log10 copies/ml), (2) CD4' absolute cell count (cells/ml), and (3) CD4 ' percentage of total lymphocytes. test medication hiding as a mediator between disclosure and medical functioning. Preacher and Hayes' (2011) INDIRECT macro was used to generate 5000 bootstrapped samples, from which bias-corrected and accelerated confidence intervals were established to estimate indirect effects.
Results
Sample characteristics
Of the 38 patients invited to participate, 30 enrolled and 25 completed the questionnaire and blood draw. The final sample was comprised of 25 PIHCA (M age 015.08 years, SD 01.82). Additional characteristics are presented in Tables 1Á3.
Descriptive and correlational analyses
Medians, means, and standard deviations of all medical functioning variables are presented in Table 4 . PCR analyses revealed that seven patients (28%) had an undetectable viral load (HIV-1 RNA PCR B50 copies/ml). Among the remainder (n 018), viral loads ranged from 1.69 to 6.07 log10 copies/ml. CD4'absolute counts ranged from 96 to 2734 cells/ ml and CD4' percentages ranged from 7 to 45%. Medication hiding was significantly correlated with CD4'counts and percentages, but not viral load (see Table 4 ).
Testing for indirect effects
Bootstrapping analyses indicated significant indirect effects of disclosure on medical functioning via medication hiding for both CD4'absolute counts and percentages (95% CIs [70.07, 929.92], [3.58, 18 .38], respectively) but not viral load. These results suggested that disclosure to 1'friend(s) versus none was associated with less medication hiding, which was associated with higher CD4'absolute counts and percentages.
Follow-up analyses were conducted with the 19 participants who had disclosed their diagnosis to 1'friend(s) to explore the implications of number of friends disclosed to. A significant indirect effect emerged when disclosure was dichotomized as 1Á10 versus 11'friends; participants who reported disclosing to 11'friends (n 08) were less likely to hide medication-taking, which was associated with higher CD4'absolute counts (95% CIs [51.14, 1313.93]) . No other significant indirect effects emerged. Reported for subset of participants for whom data were available (n 0 24); In two-parent households (n 0 11), years of education were averaged. b
In two-parent households (n 0 11), caregiver HIV status was considered positive if at least one parent was HIV-positive. 
Discussion
Despite HIV disease's evolution toward a more mainstream, manageable illness, PIHCA continue to maintain secrecy surrounding their diagnosis; most of our participants reported some degree of medication hiding and nearly a quarter refrained from disclosing to any friends. PIHCA who disclosed their serostatus to 1'friend(s) were less likely to hide taking medication, which was associated with better immunological status (higher CD4' absolute counts and percentages). Further, disclosing to 11'versus 1Á10 friend(s) was linked to less medication hiding, which was related to higher CD4'absolute counts. These findings lend support to others' recommendations for openness with friends and families given reported psychosocial benefits (e.g., peer social support; Battles & Wiener, 2002) . Further, diagnosis concealment becomes increasingly difficult for older adolescents as their time and intimacy with peers intensifies (Kang, Mellins, Ng, Robinson, & Abrams, 2008) . Thus, healthcare providers should consider the potential psychosocial and medical benefits associated with disclosure and patients' developmental stage when offering support. However, providers should also recognize the persistence of HIV-related stigma and the psychological risks associated with disclosure, particularly to acquaintances (Lam et al., 2007) or the public (Battles & Wiener, 2002) . Our results suggest that disclosing to a larger circle of friends (11') corresponds to less medication hiding, which could offer immunological benefit. A more detailed investigation is needed to determine whether this effect holds with disclosure to larger social circles or whether an optimal, intermediary level of disclosure exists for physical well-being as it does for psychological well-being. In the interim, providers should encourage PIHCA to disclose to friends, but to do so selectively.
Despite the indirect effect found between disclosure and CD4' values, we did not find a parallel effect with viral load as an outcome; thus, our hypothesis was only partially supported. Also, medication hiding and viral load were not significantly correlated. This may suggest that certain aspects of medical functioning (e.g., immune status) are more sensitive to dose timing than others (e.g., viral suppression).
Given the cross-sectional nature and small sample size of the current study, we present these findings as preliminary support for the relationship of peer disclosure to medication hiding and medical functioning. Limitations include vulnerability to social desirability bias, the term ''friends'' being subject to participants' interpretation, and disclosure being operationalized as friends' awareness versus participants' own willful action (friends could be ''aware of'' diagnosis due to caregiver's disclosure). Additionally, we were unable to include medication adherence in the hypothesized pathway. While we speculate that low medication-hiding implies better adherence since patients could take medications at scheduled times regardless of their company, it also may correspond to worse adherence, since nonadherent individuals have nothing to hide. Finally, given our small, USbased sample, the generalizability of our findings to other PIHCA nationally and internationally is limited.
Future research is warranted to establish causality within the hypothesized pathway and to investigate viral load more fully as an outcome. To support our behavioral explanation for the link between disclosure and medical functioning, adherence should be measured directly and examined as a mediator between medication hiding and medical outcomes using a larger sample. Additionally, quantitative and qualitative methods assessing other dimensions of disclosure besides number of friends disclosed to (e.g., closeness and duration of friendships, proportion of friends disclosed to, circumstances surrounding AIDS Care 1095 disclosure act, other persons disclosed to) would allow for a richer understanding of the association between disclosure and medication-related behavior.
